Erste Asset Management GmbH Purchases New Position in DexCom, Inc. (NASDAQ:DXCM)

Erste Asset Management GmbH purchased a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,308 shares of the medical device company's stock, valued at approximately $694,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Massmutual Trust Co. FSB ADV lifted its holdings in DexCom by 23.8% during the second quarter. Massmutual Trust Co. FSB ADV now owns 1,150 shares of the medical device company's stock valued at $130,000 after purchasing an additional 221 shares during the last quarter. Mather Group LLC. boosted its position in shares of DexCom by 42.7% in the second quarter. Mather Group LLC. now owns 1,263 shares of the medical device company's stock valued at $143,000 after acquiring an additional 378 shares during the period. Kingswood Wealth Advisors LLC boosted its position in shares of DexCom by 10.1% in the second quarter. Kingswood Wealth Advisors LLC now owns 4,268 shares of the medical device company's stock valued at $484,000 after acquiring an additional 392 shares during the period. Valeo Financial Advisors LLC boosted its position in shares of DexCom by 37.1% in the second quarter. Valeo Financial Advisors LLC now owns 7,617 shares of the medical device company's stock valued at $864,000 after acquiring an additional 2,062 shares during the period. Finally, Simplicity Wealth LLC boosted its position in shares of DexCom by 5.3% in the second quarter. Simplicity Wealth LLC now owns 7,193 shares of the medical device company's stock valued at $816,000 after acquiring an additional 365 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $0.10 during midday trading on Wednesday, reaching $81.01. 3,218,346 shares of the stock traded hands, compared to its average volume of 3,914,188. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market capitalization of $31.64 billion, a PE ratio of 48.51, a P/E/G ratio of 2.43 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company's 50 day moving average is $72.11 and its 200 day moving average is $86.79.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on DXCM shares. Leerink Partners cut their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Piper Sandler reiterated an "overweight" rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Stifel Nicolaus lifted their target price on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, August 23rd. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $104.59.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.